Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Darunavir Krka 600 mg film-coated tablets.
Pharmaceutical Form |
---|
Film-coated tablet (tablet). Orangish brown, oval, biconvex film-coated tablets, engraved with a mark S2 on one side. Tablet dimension: 19.5 × 10 mm. |
Each film-coated tablet contains 600 mg darunavir.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Darunavir |
Darunavir is an inhibitor of the dimerisation and of the catalytic activity of the HIV-1 protease (KD of 4.5 × 10-12 M). It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles. |
List of Excipients |
---|
Tablet core: Cellulose, microcrystalline Film coating: Poly(vinyl alcohol) |
Bottle (HDPE), child resistant tamper evident PP closure with a desiccant:
Not all pack sizes may be marketed.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
30 film-coated tablets: EU/1/17/1249/005
60 film-coated tablets: EU/1/17/1249/006
90 film-coated tablets: EU/1/17/1249/007
180 film-coated tablets: EU/1/17/1249/008
Date of first authorisation: 26 January 2018
Date of latest renewal: 9 November 2022
Drug | Countries | |
---|---|---|
DARUNAVIR | Nigeria |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.